P1.32. Durable Complete Response in Leptomeningeal Disease (LMD) of EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) to Amivantamab, an EGFR-MET Receptor Bispecific Antibody, After Progressing on Osimertinib
Back to course
Pdf Summary
Asset Subtitle
Yoonhee Choi, New York-Presbyterian of Queens, United States
Meta Tag
Speaker Yoonhee Choi, New York-Presbyterian of Queens, United States
Topic Poster Listing
Keywords
amivantamab
bispecific antibody
EGFR
MET receptors
CNS involvement
NSCLC
osimertinib
leptomeningeal disease
complete resolution
CNS metastases
Powered By